Thelansis

Cystinosis Market Outlook Thelansis’s “Cystinosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cystinosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do interviewed ex...

Cystinosis Market Outlook Thelansis’s “Cystinosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cystinosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Cystinosis Overview Cystinosis is a systemic disease where cystine crystals accumulate in all body cells and tissues and is the most common genetic cause of renal Fanconi syndrome in children. It has 3 major clinical presentations depending on the severity of mutations affecting the CTNS gene: the infantile nephropathic form, the juvenile nephropathic form, and the ocular non-nephropathic form. It is a lysosomal storage disorder caused by mutations in the CTNS gene, encodi...

  Cystinosis is a systemic disease where cystine crystals accumulate in all body cells and tissues and is the most common genetic cause of renal Fanconi syndrome in children. It has 3 major clinical presentations depending on the severity of mutations affecting the CTNS gene: the infantile nephropathic form, the juvenile nephropathic form, and the ocular non-nephropathic form. It is a lysosomal storage disorder caused by mutations in the CTNS gene, encoding for the carrier protein cystinosin, which transports cystine out of the lysosomal compartment. Defective cystinosin function results in intra-lysosomal cystine accumulation in all body cells and organs. The kidneys start affected during the first year of life through proximal tubular damage followed by progressive glomerular damage and end-stage renal failure during mid-childhood if not treated. Other affected organs include the eyes, thyroid, pancreas, gonads, muscles and CNS. Leucocyte cystine assay is the cornerstone for diag...